HR Execs on the Move

Saranas

www.saranas.com

 
Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.saranas.com
  • 3900, Essex Lane
    Houston, TX USA 77027
  • Phone: 650.219.4111

Executives

Name Title Contact Details

Similar Companies

Pharmessen Scientific

Pharmessen Scientific is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.

Noven

Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.

Bio-Boiler Systems Inc

Bio-Boiler Systems Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.